Literature DB >> 17222747

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.

Stuart M Lichtman1, Hans Wildiers, Vincent Launay-Vacher, Christopher Steer, Etienne Chatelut, Matti Aapro.   

Abstract

A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients with renal insufficiency. This manuscript outlines recommended dosing adjustments for cancer drugs in this population according to renal function. Dosing adjustments have been made for drugs in current use which have recommendations in renal insufficiency and the elderly, focusing on drugs which are renally eliminated or are known to be nephrotoxic. Recommendations are based on pharmacokinetic and/or pharmacodynamic data where available. The taskforce recommend that before initiating therapy, some form of geriatric assessment should be conducted that includes evaluation of comorbidities and polypharmacy, hydration status and renal function (using available formulae). Within each drug class, it is sensible to use agents which are less likely to be influenced by renal clearance. Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222747     DOI: 10.1016/j.ejca.2006.11.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  53 in total

1.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Thierry Gil; Sandrine Marreaud; Gedske Daugaard; Iwona Skoneczna; Sandra Collette; Julie Lorent; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Monitoring renal function during chemotherapy.

Authors:  Louise B Hartlev; Charlotte R Boeje; Henrik Bluhme; Torben Palshof; Michael Rehling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-15       Impact factor: 9.236

Review 3.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

4.  Geriatric oncology: introduction.

Authors:  Stuart M Lichtman
Journal:  Curr Treat Options Oncol       Date:  2009-08

Review 5.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

Review 6.  Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Authors:  David J Einstein; Guru Sonpavde
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 7.  Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Authors:  Morgan A Casal; Thomas D Nolin; Jan H Beumer
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-19       Impact factor: 8.237

Review 8.  Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy.

Authors:  Stuart M Lichtman; Manpreet K Boparai
Journal:  Curr Treat Options Oncol       Date:  2008-07-29

Review 9.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08

10.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.